ALZN: Alzamend Neuro, Inc. Market Cap to Revenue Ratio
The potential of Alzamend Neuro, Inc. (ALZN) is based on insurance fund payouts for dementia therapy. Innovative cellular vaccines and lithium developments confirm the firm's scientific status, although the speculative pipeline is already priced in. The GURU.Markets terminal displays the company's P/S chart, where the P/S price action reflects the business value relative to revenue, and the current level is .
Alzamend Neuro, Inc. (ALZN) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- business book valuation details:
- business debt structure and liquidity details:
- earnings and valuation multiples information:
ALZN - Net Profit|Company Profit Forecast Alzamend Neuro, Inc.|ALZN - Price to Earnings Ratio|Price to Future Earnings Ratio alzamend.com|ALZN - PEG Multiple|Enterprise Value to EBITDA Ratio Alzamend|ALZN - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Alzamend Neuro|ALZN - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth alzamend.com|ALZN - Earnings per share growth in current year|Net earnings per share growth forecast for next year Alzamend Neuro, Inc.
- total revenue and sales volume data:
Fundamental company analysis:Alzamend Neuro Inc., ALZN
Institutional capital maintains a cautious valuation of Alzamend Neuro, Inc. (ALZN), as the high emotional attachment of retail investors to the fight against Alzheimer's disease often inflates share prices relative to actual earnings. By analyzing the P/S ratio dynamics, an investor can observe the relationship between market capitalization and annual revenue, which helps determine the premium paid for the future success of clinical trials and assess the fundamental stability of the asset.
Competitors of Alzamend Neuro, Inc.
biogen.com - Market Cap to Revenue Ratio|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|RGC: Market Cap to Revenue Ratio|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Price to Sales Catalyst Pharma CPRX|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|P/S Multiple Harmony Corp (HRMY)|Price-to-Revenue Ratio Biohaven Ltd. BHVN|Market Capitalization-to-Revenue Ratio AMLX|TRVI - Price-to-Revenue Ratio|Price to Sales Praxis Precision Medicines Inc|AVXL (Anavex Corp) - Market Cap to Revenue|CeriBell EEG - Market Capitalization-to-Revenue Ratio|PRTA (Prothena Biosciences) - P/S Multiple|Alector Therapeutics (ALEC) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Annexon (ANNX)|omeros.com - Market Cap to Revenue Ratio|P/S Multiple NGNE (Neurogene Corp)|ACIU - Market Cap to Revenue|VYGR: Market Cap to Revenue|Price-to-Revenue Coefficient neumoratx.com NMRA|SCLX: P/S Multiple|Tevogen Bio Holdings Inc. (TVGN) - P/S Multiple|Price-to-Revenue Ratio Alpha Cognition Inc|Price-to-Revenue Ratio CGTX|Market Cap to Revenue IKT (Inhibikase Therapeutics)|SAVA: Price-to-Sales Ratio|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VTGN - Price-to-Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Revenue Ratio|ABOS: P/S Multiple|Price to Sales cervomed.com (CRVO)|Market Cap to Revenue ATHE|P/S Multiple Clene Nanomedicine|Price-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Price to Sales|Grace Tx - P/S Multiple|AIFF - P/S Multiple|anewmeds.com (KLTO) - Price-to-Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Price-to-Revenue Ratio|Market Cap to Revenue RVPH|MetaVia, Inc. - Price-to-Sales Ratio|P/S Multiple NRXS|P/S Multiple heliusmedical.com (HSDT)|Price-to-Revenue Ratio Passage Bio PASG|NEUP - Market Cap to Revenue|Minerva Neurosciences - P/S Multiple|Price to Sales athira.com|Addex Therapeutics Ltd (ADXN) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CYCN|PTIX (Protagenic Therapeutics Inc.) - P/S Multiple|Market Cap to Revenue Ratio KTTA (Pasithea)|Market Cap to Revenue CRGT (Cortigent, Inc.)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|CARA: Market Cap to Revenue Ratio|Chromocell Therapeutics Corporation - P/S Multiple|Price to Sales Eliem Therapeutics|ITCI (intracellulartherapies.com) - Market Cap to Revenue|longboardpharma.com (LBPH) - P/S Multiple|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio NeuroBo (NRBO)|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TRVN|Vigil Neuro - P/S Multiple|Price-to-Revenue Coefficient anewmeds.com WENA|Cerevel (CERE) - Price-to-Revenue Ratio
